Skip to main content

Table 3 Association of atherosclerotic plaques and stenosis with UAE and eGFR

From: Albuminuria but not low eGFR is closely associated with atherosclerosis in patients with type 2 diabetes: an observational study

  UAE eGFR
OR (95% CI) p values OR (95% CI) p values
Plaques
 Model 1 1.22 (1.11–1.35)  < 0.001 0.49 (0.44–0.54)  < 0.001
 Model 2 1.16 (1.03–1.30) 0.017 0.90 (0.79–1.02) 0.098
 Model 3 1.19 (1.05–1.35) 0.007 0.88 (0.77–1.01) 0.059
 Model 4 1.15 (1.00–1.32) 0.046 0.88 (0.76–1.02) 0.079
 Model 5 1.20 (1.03–1.39) 0.020 0.88 (0.75–1.02) 0.089
Stenosis
 Model 1 1.30 (1.17–1.45)  < 0.001 0.61 (0.54–0.68)  < 0.001
 Model 2 1.27 (1.13–1.43)  < 0.001 1.04 (0.91–1.18) 0.614
 Model 3 1.26 (1.11–1.42)  < 0.001 1.04 (0.91–1.19) 0.593
 Model 4 1.22 (1.07–1.39) 0.003 1.08 (0.93–1.25) 0.312
 Model 5 1.17 (1.01–1.35) 0.036 1.12 (0.95–1.31) 0.177
  1. UAE urinary albumin excretion, eGFR estimated glomerular filtration rate, DD duration of diabetes, APA anti-platelet agents, LLD lipid-lowering drugs, AHA anti-hypertensive agents, SBP systolic blood pressure, DBP diastolic blood pressure, WC waist circumference, WHR waist-to-hip ratio, BMI body mass index, FPG fasting plasma glucose, 2-h PPG 2-h postprandial plasma glucose, HbA1c glycated hemoglobin A1c, FCP fasting C-peptide, 2-h PCP 2-h postprandial C-peptide, HOMA2-IR HOMA of insulin resistance, TG total triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, ALT alanine transaminase, SUA serum uric acid
  2. Model 1: unadjusted
  3. Model 2: Adjusted for age, sex, DD, hypertension, smoking status and alcohol use
  4. Model 3: Further adjustment for use of AHA, LLD, APA
  5. Model 4: Further adjustment for SBP, DBP, BMI, WC and WHR
  6. Model 5: Further adjustment for ALT, TG, TC, HDL-C, LDL-C, SUA, FPG, 2-h PPG, HbA1c, FCP, 2-h PCP, HOMA2-IR